lAight

lAight is an innovative, non-invasive therapy for acute abscesses including hidradenitis suppurativa/ acne inversa.

Technology

Effect

Usability

Platform

Technology

For lAight®, we use a combination of various electromagnetic waves, including fractions of the visible light spectrum. Potentially harmful wavelengths of UV-A and UV-B are not utilized. A wide range of studies can be found for the efficiency and safety of the single components of the lAight® therapy, which have been researched individually. The NICE study – conducted at the University Medical Center of the University of Mainz – investigated the effect of a purpose-built combination therapy, called lAight® therapy, as a treatment for hidradenitis suppurativa*.

Effect

The NICE study found that a regular treatment regime of the inflamed lesions utilizing lAight® therapy reduces the number of lesions and significantly improves the quality of life for the majority of patients (measured by the DLQI scale). Patients also describe an instant, noticeable pain reduction following the treatment, as well as an accelerated healing process and an improved scar texture.

Usability

Minor side-effects occur rarely, in some cases a temporary skin irritation can appear on the treated skin areas*. There are only a few known contraindications, for example, skin cancer. Therefore, lAight® is a suitable long-term therapy for hidradenitis suppurativa. Whether lAight® is an adequate treatment for an individual patient, will be determined by the attending physician.

Platform

With the consent of the patient, the progress of all therapy utilized, as well as photographic documentation, can be recorded and reviewed. The individual patient can access our lAight® Portal and look into his course of treatment, as well as find useful information about hidradenitis suppurativa.

Availability
Therapeutic mechanism*
Antibacterial
effect
Reduction of
sebum production
Stimulation of
blood circulation
Stimulation of
tissue regeneration
Reduction of hair
follicle blockage
Anti
inflammatory
I

2012-2013
Development

Successful series of test and therapy optimization
II

2014-2016
Clinical trial

Verification of lAight®’s effectiveness by University Clinic Mainz, Germany
III

2015-2016
Certification

Medical product certification in the European Union
IV

April 2017
Market launch

lAight® therapy available at selected medical centers in GER and AUT

What physicians say about lAight®

  1. “The lAight® therapy is a promising alternative for the treatment of hidradenitis suppurativa and I am delighted to be able to provide it for my patients. We can treat the disease now without surgical interventions, long-term and non-invasive. The results of the lAight® therapy are very positive and my patients are relieved to have found a working treatment.”

    Dr. Zeynep Potente, Aestetic and plastic surgeon.

  2. “It is my goal to give HS patients a normal life. I offer a special consultation hour for patients with chronic abscesses and hidradenitis suppurativa. After only 7 months I already witnessed so many distinct and visible successes that I am very happy to have included this gently new form of therapy into my practice. The overwhelmingly positive feedback is a great encouragement for me.”

    Dr. med. Uwe Kirschner, Dermatologist and venereologist

  3. “We are familiar with the ordeal of the HS patients. We are happy to be able to provide a treatment that is a good supplementation to a surgical intervention.”

    Gerhard Rothenaicher, Surgeon

  4. “The combination of the lAight® therapy with a special treatment of wounds in our WundZentrum offers a good possibility and great therapeutic option for patients with HS.”

    Dr. Peter Kandzorra, Surgeon

Research cooperations

Research cooperations

  • University Medical Center of the University Mainz

    Under the supervision of

    Univ.-Prof. Dr. med. Esther von Stebut-Borschitz

    Senior Physician, Assistant Professor TransMed Research School,
    Head of Programming, Expert in inflammatory Dermatosis,
    Since October 2017: Director of the clinic and policlinic for dermatology and venerology of the University Medical Center of Cologne
  • Henry Ford Health System, Detroit, USA

    Under the supervision of

    Iltefat Hamzavi, M.D., FAAD

    Director Researcher Initiated Studies, Dermatological
    Expert in Photodermatology und Laser-Technology for Hidradenitis suppurativa/Acne inversa und Vitiligo

The lAight®therapy was also presented in Detroit at the SHSA 2017-Symposium on Hidradenitis Suppurativa Advances in November 2017.

LENICURA Team

* Selected works on light-based and radiofrequency therapy:
1. NICE-trial: Evidence for the efficacy of the lAight® therapy was provided in a clinical trial by the University Medical Center of the University Mainz, under the supervision of Univ. Prof. Dr. med. Esther von Stebut-Borschitz.
The first presentation of the results was given at the end of September 2016 at the EADV-congress in Vienna. The publication of the clinical trial results is being prepared.
2. Ali MM, Porter RM, Gonzalez ML. Intense pulsed light enhances transforming growth factor beta1/Smad3 signaling in acne-prone skin. J Cosmet Dermatol. 2013 Sep;12(3):195-203.
3. Highton L, Chan WY, Khwaja N, Laitung JK. Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study. Plast Reconstr Surg. 2011 Aug;128(2):459-65.
4. Taylor M, Porter R, Gonzalez M. Intense pulsed light may improve inflammatory acne through TNF-α down-regulation. J Cosmet Laser Ther. 2014 Apr;16(2):96-103.
5. Kaminaka C, Uede M, Nakamura Y, Furukawa F, Yamamoto Y. Histological studies of facial acne and atrophic acne scars treated with a bipolar fractional radiofrequency system. J Dermatol. 2014 May;41(5):435-8.
Disclaimer
The lAight® therapy is an innovative, alternative treatment method that is currently not a part of medical services compensated by statutory health insurance (in Germany). The treatment is carried out by a physician. The mechanism of action and tolerance of the therapy have not yet been sufficiently scientifically researched with regard to conventional medicine. The statements about the effect and tolerance of the therapy, are based on previous experience of the therapy usage and preceding results of the trial carried out by the University Medical Center of the University Mainz. Due to the fact that every individual is different and medical success by definition cannot be guaranteed, before beginning treatment, patients are informed by the attending physician, about possible risks and contraindications, as well as costs, so they have ample time to decide if what we offer is the best course to take towards recovery.